|
YAMAMOTO Toshiyuki
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. |
| Journal | Formal name：Scientific Reports Abbreviation：Sci Rep ISSN code：20452322 |
| Volume, Issue, Page | 5,pp.8829 |
| Author and coauthor | FURUKAWA Toru†*, SAKAMOTO Hitomi, TAKEUCHI Shoko, AMERI Mitra, KUBOKI Yuko, YAMAMOTO Toshiyuki, HATORI Takashi, YAMAMOTO Masakazu, SUGIYAMA Masanori, OHIKE Noriyuki, YAMAGUCHI Hiroshi, SHIMIZU Michio, SHIBATA Noriyuki, SHIMIZU Kyoko, SHIRATORI Keiko |
| Publication date | 2015/03 |
| Summary | Acinar cell carcinoma of the pancreas is a rare tumor with a poor prognosis. Compared to pancreatic ductal adenocarcinoma, its molecular features are poorly known. We studied a total of 11 acinar cell carcinomas, including 3 by exome and 4 by target sequencing. Exome sequencing revealed 65 nonsynonymous mutations and 22 indels with a mutation rate of 3.4 mutations/Mb per tumor, on average. By accounting for not only somatic but also germline mutations with loss of the wild-type allele, we identified recurrent mutations of BRCA2 and FAT genes. BRCA2 showed somatic or germline premature termination mutations, with loss of the wild-type allele in 3 of 7 tumors. FAT1, FAT3, and FAT4 showed somatic or germline missense mutations in 4 of 7 tumors. The germline FAT mutations were with loss of the wild-type allele. Loss of BRCA2 expression was observed in 5 of 11 tumors. One patient with a BRCA2-mutated tumor experienced complete remission of liver metastasis following cisplatinum chemotherapy. In conclusion, acinar cell carcinomas show a distinct mutation pattern and often harbor somatic or germline mutations of BRCA2 and FAT genes. This result may warrant assessment of BRCA2 abrogation in patients with the carcinoma to determine their sensitivity to chemotherapy. |
| DOI | 10.1038/srep08829 |
| PMID | 25743105 |